Impact of melatonin use in breast cancer patients undergoing chemotherapy on extracellular vesicles -an in vitro study.

• Grant number: 23/06304-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: March 01, 2024
• End date: February 28, 2025
• Field of knowledge: Biological Sciences - Genetics - Human and Medical Genetics
• Principal Investigator: Debora Aparecida Pires de Campos Zuccari
• Grantee: Guilherme Silva Bruno Barbosa
• Host Institution: Faculdade de Medicina de São José do Rio Preto (FAMERP). Secretaria de Desenvolvimento Econômico (São Paulo - Estado). São José do Rio Preto , SP, Brazil

Abstract

Breast cancer (BCC) is the most commonly diagnosed neoplasm in women worldwide.world, and the second deadliest in women, after non-melanoma skin cancer.non-melanoma skin cancer. This neoplasm is a heterogeneous disease with a complex molecular etiologycomplex etiology, which has raised great scientific interest with a focus on the mechanisms of developmentof development, growth, and progression of this disease. In the tumor microenvironmentthere are communicating nanoparticles responsible for the transfer ofproteins, lipids and nucleic acids, called Extracellular Vesicles (EVs).EVs are released into various biological fluids and can be consideredmolecular biomarkers and deliverers of therapeutic molecules. Melatoninis a neurohormone synthesized by the pineal gland and its secretion rhythm isdirectly related to the circadian cycle. Recent studies show animportant relationship between breast cancer and melatonin and has already been describedactivity has been described, through oncostatic, apoptotic, antiangiogenic and antiproliferativeand antiproliferative mechanisms. In addition, melatonin, with its immunomodulatoryimmunomodulatory, antioxidant and antiproliferative properties, is gaining importance forcurative and/or preventive clinical use in cancer. Its effect on the burden of EVshas not yet been described. Thus, the present work intends to verify the effectof melatonin, administered to patients with CM undergoing chemotherapy,on the burden of EVs in an in vitro study and its possible protection against the phenotypicphenotypic change caused in benign cells treated with these VEs.